Sona Nanotech Inc. (SNANF)
Sona Nanotech Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Halifax, NS, CA. The stock last traded at $0.25, up 13.64% on the session, giving a market capitalisation of $28.6M. On trailing twelve-month figures it carries a trailing P/E of -14.67, a net margin of 0.0%. Its beta of 0.98 implies it has historically moved less than the broad market.
Sona Nanotech Inc. is a life sciences enterprise specializing in nanotechnology, primarily engaged in the development and commercialization of gold nanorod products for diagnostic purposes. The company's offerings also encompass distinct gold nanorod varieties, such as Gemini and Omni (the latter tailored specifically for medical uses), alongside providing specialized contract services. A prominent product is their Nanotech COVID-19 Lateral Flow Assay, an immunochromatographic test designed to identify SARS-CoV-2 spike protein antigens within saliva samples from individuals suspected of COVID-19 infection. These advanced gold nanorod technologies are utilized in a diverse array of applications, including targeted drug delivery, analytical testing for food, beverages, and environmental contaminants, cellular imaging, cancer treatment, liposuction therapy, and various diagnostic fields spanning human medicine, consumer goods, military applications, and veterinary science. The company's headquarters are located in Halifax, Canada.
Sona Nanotech Inc. is most often compared with the following Healthcare names: